A61P 43 - Drugs for specific purposes, not provided for in groups

Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
10/2002
10/22/2002	CA2216601C Intracellular domain of the her-2/neu protein for prevention or treatment of malignancies
10/22/2002	CA2212904C The activity-inhibitor and activity-potentiator for glutamic acid in the brain
10/22/2002	CA2185712C Enhanced virus-mediated dna transfer
10/22/2002	CA2118670C Pharmaceutical compositions in semisolid form and a device for administration thereof
10/20/2002	CA2382326A1 Therapeutic use of selective pde10 inhibitors
10/17/2002	WO2002081747A1 Method of examining steroid responsiveness
10/17/2002	WO2002081728A2 Quinoline inhibitors of hyak1 and hyak3 kinases
10/17/2002	WO2002081703A2 Mitogenic oxygenase regulators
10/17/2002	WO2002081686A2 Nucleic acids binding a neuropeptide
10/17/2002	WO2002081677A2 Improved gene expression
10/17/2002	WO2002081661A2 Immunotherapeutic combinations for the treatment of tumours that overexpress gangliosides
10/17/2002	WO2002081636A2 Protein modification and maintenance molecules
10/17/2002	WO2002081619A1 Glycosaminoglycan/collagen complexes and use thereof
10/17/2002	WO2002081522A1 Anti-osteopontin antibody and use thereof
10/17/2002	WO2002081521A2 Osteoprotegerin in milk
10/17/2002	WO2002081499A2 Somatostatin agonists
10/17/2002	WO2002081496A2 Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumours
10/17/2002	WO2002081494A1 Oligonucleotide mediated inhibition of hepatitis b virus and hepatitis c virus replication
10/17/2002	WO2002081493A1 9-amino-14-membered macrolide derived from leucomycin
10/17/2002	WO2002081482A1 Compounds and methods for inhibiting mrp1
10/17/2002	WO2002081481A1 Compounds and methods for inhibiting mrp1
10/17/2002	WO2002081478A2 Broadspectrum 2-(substituted-amino)-benzoxazole sulfonamide hiv protease inhibitors
10/17/2002	WO2002081475A1 Jun kinase inhibitors
10/17/2002	WO2002081467A1 Quinazoline and quinazoline-like compounds for the treatment of integrin-mediated disorders
10/17/2002	WO2002081464A1 Benzoaxathiepin derivatives and their use as medicines
10/17/2002	WO2002081463A1 Antagonists of mcp-1 function and methods of use thereof
10/17/2002	WO2002081461A1 Piperazine derivatives as tachykinin antagonists
10/17/2002	WO2002081457A1 `1,4!-diazepane-1-carboxylic acid derivatives process for their preparation and their use as tachykinin antagonists
10/17/2002	WO2002081448A1 Benzamidine derivative
10/17/2002	WO2002081445A1 Indolinones, substituted in position 6, and their use as kinase inhibitors
10/17/2002	WO2002081443A1 Novel guanidino compounds
10/17/2002	WO2002081435A1 Sulphones which modulate the action of gamma secretase
10/17/2002	WO2002081433A1 Sulphones which modulate the action of gamma secretase
10/17/2002	WO2002081430A2 Novel benzylideneamino guanidines and their uses as ligands to the melanocortin receptors
10/17/2002	WO2002081428A1 Benzene compound and salt thereof
10/17/2002	WO2002081426A1 Peptide deformylase inhibitors
10/17/2002	WO2002081420A1 Cyclooctanone derivative and cyclodecanone derivative, and use thereof
10/17/2002	WO2002081415A2 Method for inhibiting metap2
10/17/2002	WO2002081005A2 Peritoneal dialysis fluid
10/17/2002	WO2002080982A2 Nucleic acid mucosal immunization
10/17/2002	WO2002080980A1 Lectin-directed prodrug delivery system
10/17/2002	WO2002080979A2 Conjugate of hydroxyalkyl starch and an active agent
10/17/2002	WO2002080974A1 Novel medicinal use of cytokine production inhibitor
10/17/2002	WO2002080973A1 Composition for use in therapy of hard tissue of mammal and method of therapy thereof
10/17/2002	WO2002080952A2 Therapeutic use and identification of modulators of a hedgehog signalling pathway or one of its target pathways
10/17/2002	WO2002080949A1 Use of extracts of the plant litchi chinensis sonn.
10/17/2002	WO2002080936A1 Combination therapy comprising glucose reabsorption inhibitors and ppar modulators
10/17/2002	WO2002080935A1 Combination therapy comprising glucose reabsorption inhibitors and retinoid-x receptor modulators
10/17/2002	WO2002080932A1 Methods of treating acne
10/17/2002	WO2002080926A1 Pyrazolopyrimidines as therapeutic agents
10/17/2002	WO2002080924A1 Novel use of arylethene sulfonamide derivative
10/17/2002	WO2002080917A1 Novel use of proton pump inhibitors
10/17/2002	WO2002080914A2 Use of substituted imidazo[1,2-a]-pyridine compounds as medicaments
10/17/2002	WO2002080913A1 Thiazolidinediones alone or in combination with other therapeutic agents for inhibiting or reducing tumour growth
10/17/2002	WO2002080911A2 Use of substituted imidazo[1,2-a]-pyridine-3-yl-amide and imidazo[1,2-a]-pyridine-3-yl-amine compounds as medicaments for the treatment of neurodegenerative diseases
10/17/2002	WO2002080909A1 Utilization of pyrazoline derivatives in the preparation of a medicament for the prevention and/or treatment of proliferative cell diseases
10/17/2002	WO2002080903A1 Functional role for cannabinoids in autonomic stability during sleep
10/17/2002	WO2002080899A1 Remedial agent for digestive disease
10/17/2002	WO2002080896A1 Uses of benzylideneamino guanidines as ligands to the melanocortiin receptors
10/17/2002	WO2002080887A2 Timed pulse release composition
10/17/2002	WO2002080884A2 Powder inhaler formulations
10/17/2002	WO2002080854A2 Compositions and methods for the prevention and treatment of human prostate cancer
10/17/2002	WO2002080850A2 Bulking agents as satiety agents
10/17/2002	WO2002080849A2 Chemotherapeutic induction of egr-1 promoter activity
10/17/2002	WO2002070524A3 N-but-3-enyl norbuprenorphine and its use as analgesic
10/17/2002	WO2002068414A3 Analogs of thalidomide as potential angiogenesis inhibitors
10/17/2002	WO2002066468A3 Heterocyclic urea derivatives and their use as dopamine d3 receptor ligands
10/17/2002	WO2002066456A3 Thiophene substituted amine derivatives as glyt-1 inhibitors
10/17/2002	WO2002062301A3 Method and composition for rejuvinating cells, tissues, organs, hair and nails
10/17/2002	WO2002054851A3 Inhibition of pathological angiogenesis in vivo
10/17/2002	WO2002049626A3 The use of ppar-gamma agonists for treating diseases characterised by neuron degeneration, neuron injury or impaired pasticity
10/17/2002	WO2002047493A3 Health promoting compositions
10/17/2002	WO2002044156A3 Benzimidazole derivatives useful as tie-2 and/or vegfr-2 inhibitors
10/17/2002	WO2002043567A3 A method of treating cancer
10/17/2002	WO2002042292A3 Indol derivative and their use as inhibitors of p38 kinase
10/17/2002	WO2002036605A9 Estrone-derivatives having cytoprotective activity
10/17/2002	WO2002036108A3 Use of 20-hete synthesizing enzyme inhibitors as therapy for cerebral vascular diseases
10/17/2002	WO2002034726A3 Pyrimidine-2,4,6-trione metalloproteinase inhibitors
10/17/2002	WO2002019213A3 Method for treatment of migraine using pde5 inhibitors
10/17/2002	WO2002017891A3 Method for diagnosing neuronal diseases and for treating primary hemostasis deficiency
10/17/2002	WO2002015920A3 Treatment of hyperproliferative diseases
10/17/2002	WO2002002133A3 Peptide composition for treatment of periodontal diseases and prevention of skin aging
10/17/2002	WO2002000871A3 Method for introducing nucleic acids and other biologically active molecules into the nucleus of higher eukaryotic cells by means of an electrical current
10/17/2002	WO2002000241A3 Compositions and methods for regulating the cell cycle using a ki gene or polypeptide
10/17/2002	WO2001098354A3 Human receptors
10/17/2002	WO2001096283A9 Hiv integrase inhibitors
10/17/2002	WO2001090151A3 Human receptor proteins; related reagents and methods
10/17/2002	WO2001074404A3 Compositions containing genetically modified lung cancer cells expressing a tgf-beta inhibitor
10/17/2002	WO2001058241A9 Adenosine a2a receptor antagonists for treating and preventing hepatic fibrosis, cirrhosis and fatty liver
10/17/2002	WO2001057015A9 INTERNAL 1,15-LACTONES OF FLUPROSTENOL AND RELATED PROSTAGLANDIN F2α ANALOGS AND THEIR USE IN THE TREATMENT OF GLAUCOMA AND INTRAOCULAR HYPERTENSION
10/17/2002	WO2001054723A9 Therapeutic method for reducing angiogenesis
10/17/2002	WO2001052878A9 The use of copolymer 1 and related peptides and polypeptides and t cells treated therewith for neuroprotective therapy
10/17/2002	WO2001041760A8 Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect
10/17/2002	US20020152481 Genetic engineering; qualitative analysis
10/17/2002	US20020152480 Alpha-synuclein super-mutants accelerate alpha-synuclein aggregation
10/17/2002	US20020151715 Imidazole derivatives
10/17/2002	US20020151695 Transforming growth factor-beta-related molecules and uses thereof
10/17/2002	US20020151679 Peptide for use in the treatment of infections, viral and cancer diseases
10/17/2002	US20020151588 Dissociated glucocorticoid receptor antagonists for the treatment of glucocorticoid associated side effects
10/17/2002	US20020151574 Extracellular signal regulated kinase (ERK); anticancer agents and protein kinase inhibitors

1 ... 874 875 876 877 878 879 880 881 882 883 884 885 886 887 888 889 890 891 892 893 894 ... 1564